These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35163285)

  • 1. The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice.
    Hanaguri J; Yokota H; Kushiyama A; Kushiyama S; Watanabe M; Yamagami S; Nagaoka T
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
    Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
    Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
    Ishibashi Y; Matsui T; Yamagishi SI
    Diab Vasc Dis Res; 2016 Nov; 13(6):438-441. PubMed ID: 27407083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
    Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y
    FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
    Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
    J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice.
    Kato J; Shirakami Y; Ohnishi M; Mizutani T; Kubota M; Sakai H; Ibuka T; Tanaka T; Shimizu M
    Oncol Rep; 2019 Dec; 42(6):2797-2805. PubMed ID: 31638239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
    Kaku K; Watada H; Iwamoto Y; Utsunomiya K; Terauchi Y; Tobe K; Tanizawa Y; Araki E; Ueda M; Suganami H; Watanabe D;
    Cardiovasc Diabetol; 2014 Mar; 13():65. PubMed ID: 24678906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
    Iwamoto M; Kubota T; Sakurai Y; Wada N; Shioda S; Yamauchi T; Kadowaki T; Kubota N
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00971. PubMed ID: 35707828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate Nano-Eyedrops Ameliorate Retinal Blood Flow Dysregulation and Neurovascular Coupling in Type 2 Diabetic Mice.
    Hanaguri J; Nagai N; Yokota H; Kushiyama A; Watanabe M; Yamagami S; Nagaoka T
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
    Park JH; Seo I; Shim HM; Cho H
    J Pineal Res; 2020 Mar; 68(2):e12623. PubMed ID: 31743484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
    Fushimi Y; Obata A; Sanada J; Nogami Y; Ikeda T; Yamasaki Y; Obata Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    Sci Rep; 2021 Aug; 11(1):16120. PubMed ID: 34373487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
    Shimohata H; Iwaki Y; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
    Int Urol Nephrol; 2022 Aug; 54(8):1907-1914. PubMed ID: 34843041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice.
    Neschen S; Scheerer M; Seelig A; Huypens P; Schultheiss J; Wu M; Wurst W; Rathkolb B; Suhre K; Wolf E; Beckers J; Hrabé de Angelis M
    Diabetes; 2015 Jan; 64(1):284-90. PubMed ID: 25071027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
    Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
    J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.